Document Detail

Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.
MedLine Citation:
PMID:  12796549     Owner:  NLM     Status:  MEDLINE    
An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon beta-1b (IFNbeta-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNbeta-1b-treated MS patients with continued disease activity were studied on IFNbeta-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).
S Markovic-Plese; B Bielekova; N Kadom; T P Leist; R Martin; J A Frank; H F McFarland
Related Documents :
22500909 - Comparison of postoperative analgesic effect of intrathecal magnesium and fentanyl adde...
22612729 - Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prev...
7741169 - Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
22503769 - Survey on benign prostatic hyperplasia distribution and treatment patterns for men with...
22371809 - Effect of ligamenta flava hypertrophy on lumbar disc herniation with contralateral symp...
22592929 - A randomized controlled trial for cervical priming using vaginal misoprostol prior to h...
17503229 - Intratympanic gentamicin therapy for intractable ménière's disease.
10595789 - Occurrence of anti-prothrombin and anti-beta2-glycoprotein i antibodies in patients wit...
21801099 - Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pul...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Neurology     Volume:  60     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-10     Completed Date:  2004-02-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1849-51     Citation Subset:  AIM; IM    
Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD 20892-1400, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Azathioprine / therapeutic use*
Drug Therapy, Combination
Interferon-beta / therapeutic use*
Longitudinal Studies
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting / diagnosis,  drug therapy*
Treatment Failure
Treatment Outcome
Reg. No./Substance:
145155-23-3/interferon beta-1b; 446-86-6/Azathioprine; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Different spatial processing for stimulus-centered and body-centered representations.
Next Document:  Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.